美国 · SEC FORM 4
MoonLake Immunotherapeutics
MLTX · Nasdaq · CIK 0001821586 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
15 同一窗口内观察到的 Form 4 交易行
15 sales · 0 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-10-08 · Bodenstedt Matthias · $98.8K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Reich KristianChief Scientific Officer
▼▼▼▼▼▼▼▼
Bodenstedt MatthiasChief Financial Officer
▼▼▼▼
Santos da Silva JorgeChief Executive Officer
▼▼▼
● 买入▼ 卖出○ 其他
—
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-10-08 · Bodenstedt Matthias.
近期 Form 4 活动
0买入
24卖出
7其他 Form 4 交易行
19SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出15 sale line(s) · 仅供背景
其他0 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 8,048,665
- 上期报告
- 8,947,906
- 日均成交量
- 1,901,006
- 回补天数
- 4.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-10-08 | Bodenstedt Matthias | 买入 (P) | Class A ordinary shares, par value $0.0001 per share | 10,870 | USD 9.09 | USD 98,808 | SEC 申报 ↗ |
| 2023-10-05 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP; Cormorant Private Healthcare Fund III LP; Cormorant Private Healthcare Fund IV LP | 买入 (P) | Class A Ordinary Shares | 58,839 | USD 59.90 | USD 3,524,456 | SEC 申报 ↗ |
| 2023-10-04 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP; Cormorant Private Healthcare Fund III LP; Cormorant Private Healthcare Fund IV LP | 买入 (P) | Class A Ordinary Shares | 67,814 | USD 57.32 | USD 3,887,098 | SEC 申报 ↗ |
| 2023-10-03 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP; Cormorant Private Healthcare Fund III LP; Cormorant Private Healthcare Fund IV LP | 买入 (P) | Class A Ordinary Shares | 150,487 | USD 57.25 | USD 8,615,381 | SEC 申报 ↗ |
| 2023-10-02 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP; Cormorant Private Healthcare Fund III LP; Cormorant Private Healthcare Fund IV LP | 买入 (P) | Class A Ordinary Shares | 74,911 | USD 57.37 | USD 4,297,644 | SEC 申报 ↗ |
| 2023-06-30 | Chen Bihua | 买入 (P) | Class A Ordinary Shares | 800,000 | USD 50.00 | USD 40,000,000 | SEC 申报 ↗ |
| 2023-06-26 | Chen Bihua | 买入 (P) | Class A Ordinary Shares | 450,000 | USD 45.63 | USD 20,535,012 | SEC 申报 ↗ |
| 2023-03-21 | Chen Bihua | 买入 (P) | Class A Ordinary Shares | 238,511 | USD 21.70 | USD 5,175,689 | SEC 申报 ↗ |
| 2023-03-20 | Chen Bihua | 买入 (P) | Class A Ordinary Shares | 588,589 | USD 19.70 | USD 11,596,779 | SEC 申报 ↗ |
| 2022-04-05 | Chen Bihua | 买入 (P) | Class A Ordinary Shares | 2,850,000 | USD 10.00 | USD 28,500,000 | SEC 申报 ↗ |
| 2020-10-22 | Helix Holdings LLC | 买入 (P) | Class A Ordinary Shares | 430,000 | USD 10.00 | USD 4,300,000 | SEC 申报 ↗ |
| 2020-10-22 | Chen Bihua | 买入 (P) | Class A Ordinary Shares | 430,000 | USD 10.00 | USD 4,300,000 | SEC 申报 ↗ |
Form 4 申报证据
31 transaction lines in the latest 365-day window; 132 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-27 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 1,100 | USD 20.00 | USD 22,000 | SEC 申报 ↗ |
| 2026-07-22 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 2,448 | USD 20.00 | USD 48,960 | SEC 申报 ↗ |
| 2026-07-21 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 50,000 | USD 20.02 | USD 1,001,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-27 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 1,100 | USD 20.00 | USD 22,000 | SEC 申报 ↗ |
| 2026-07-22 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 2,448 | USD 20.00 | USD 48,960 | SEC 申报 ↗ |
| 2026-07-21 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 50,000 | USD 20.02 | USD 1,001,000 | SEC 申报 ↗ |
| 2026-07-20 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 43,700 | USD 20.09 | USD 877,933 | SEC 申报 ↗ |
| 2026-07-15 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 16,105 | USD 20.01 | USD 322,261 | SEC 申报 ↗ |
| 2026-07-10 | Santos da Silva Jorge | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 68,289 | USD 20.02 | USD 1,367,146 | SEC 申报 ↗ |
| 2026-07-09 | Santos da Silva Jorge | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 33,936 | USD 20.01 | USD 679,059 | SEC 申报 ↗ |
| 2026-07-01 | Santos da Silva Jorge | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 47,775 | USD 20.03 | USD 956,933 | SEC 申报 ↗ |
| 2026-06-22 | Bodenstedt Matthias | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 39,120 | USD 22.04 | USD 862,205 | SEC 申报 ↗ |
| 2026-06-18 | Bodenstedt Matthias | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 2,794 | USD 19.60 | USD 54,762 | SEC 申报 ↗ |
| 2026-06-17 | Bodenstedt Matthias | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 15,082 | USD 19.68 | USD 296,814 | SEC 申报 ↗ |
| 2026-06-17 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 50,000 | USD 19.43 | USD 971,500 | SEC 申报 ↗ |
| 2026-06-16 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 50,000 | USD 18.70 | USD 935,000 | SEC 申报 ↗ |
| 2026-06-15 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 50,000 | USD 18.89 | USD 944,500 | SEC 申报 ↗ |
| 2026-05-11 | Bodenstedt Matthias | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 13,653 | USD 20.02 | USD 273,333 | SEC 申报 ↗ |
| 2026-04-14 | Bodenstedt Matthias | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 2,426 | USD 19.56 | USD 47,453 | SEC 申报 ↗ |
| 2026-04-13 | Santos da Silva Jorge | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 51,873 | USD 18.23 | USD 945,645 | SEC 申报 ↗ |
| 2026-04-10 | Santos da Silva Jorge | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 98,127 | USD 18.41 | USD 1,806,518 | SEC 申报 ↗ |
| 2026-04-10 | Bodenstedt Matthias | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 1,925 | USD 19.51 | USD 37,557 | SEC 申报 ↗ |
| 2026-04-09 | Bodenstedt Matthias | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 85,870 | USD 18.94 | USD 1,626,378 | SEC 申报 ↗ |
| 2026-01-07 | Bodenstedt Matthias | 奖励／授予 (A) | Class A ordinary shares, par value $0.0001 per share | 354,296 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Santos da Silva Jorge | D (D) | Class C ordinary shares, par value $0.0001 per share | 196,316 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-19 | Santos da Silva Jorge | C (C) | Class A ordinary shares, par value $0.0001 per share | 196,316 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-19 | Reich Kristian | D (D) | Class C ordinary shares, par value $0.0001 per share | 35,389 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-19 | Reich Kristian | C (C) | Class A ordinary shares, par value $0.0001 per share | 35,389 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-19 | Bodenstedt Matthias | D (D) | Class C ordinary shares, par value $0.0001 per share | 294,473 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-19 | Bodenstedt Matthias | C (C) | Class A ordinary shares, par value $0.0001 per share | 294,473 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Santos da Silva Jorge | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 70,000 | USD 14.49 | USD 1,014,300 | SEC 申报 ↗ |
| 2025-12-09 | Reich Kristian | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 72,908 | USD 14.43 | USD 1,052,062 | SEC 申报 ↗ |
| 2025-12-08 | Santos da Silva Jorge | 卖出 (S) | Class A ordinary shares, par value $0.0001 per share | 130,000 | USD 15.08 | USD 1,960,400 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MLTX |
| CIK | 0001821586 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 132 transaction lines from 2020-10-22 to 2026-07-27 40 P purchase lines · 56 S sale lines · 36 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.